FDA grants Fast Track to Quoin's QRX003 for Peeling Skin Syndrome

Quoin Pharmaceuticals, Ltd.

FDA granted Fast Track Designation to QRX003 for Peeling Skin Syndrome (PSS) on Sept 22, 2026.
First-ever Fast Track for a PSS therapy; second Fast Track for QRX003 (prior: Netherton Syndrome).
Follows July 2026 FDA clearance of first-ever IND for PSS; Phase 2/3 study planned 2H 2026.
Phase 2/3 to enroll up to 12 pediatric/adult patients; targeting 2028 approval; no approved PSS treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.